AP2001002038A0 - Pharmaceutical uses of NAB1 and NAB2. - Google Patents

Pharmaceutical uses of NAB1 and NAB2.

Info

Publication number
AP2001002038A0
AP2001002038A0 APAP/P/2001/002038A AP2001002038A AP2001002038A0 AP 2001002038 A0 AP2001002038 A0 AP 2001002038A0 AP 2001002038 A AP2001002038 A AP 2001002038A AP 2001002038 A0 AP2001002038 A0 AP 2001002038A0
Authority
AP
ARIPO
Prior art keywords
nab1
nab2
pharmaceutical uses
therapyl
nabi2
Prior art date
Application number
APAP/P/2001/002038A
Other languages
English (en)
Inventor
Martin Braddock
Callum Jeffrey Campbell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814989.1A external-priority patent/GB9814989D0/en
Priority claimed from GBGB9819826.0A external-priority patent/GB9819826D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AP2001002038A0 publication Critical patent/AP2001002038A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
APAP/P/2001/002038A 1998-07-11 1999-07-09 Pharmaceutical uses of NAB1 and NAB2. AP2001002038A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9814989.1A GB9814989D0 (en) 1998-07-11 1998-07-11 Gene therapy method
GBGB9819826.0A GB9819826D0 (en) 1998-09-12 1998-09-12 Gene therapy method
PCT/GB1999/002199 WO2000003014A1 (en) 1998-07-11 1999-07-09 Pharmaceutical uses of nab1 and nab2

Publications (1)

Publication Number Publication Date
AP2001002038A0 true AP2001002038A0 (en) 2001-03-31

Family

ID=26314007

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002038A AP2001002038A0 (en) 1998-07-11 1999-07-09 Pharmaceutical uses of NAB1 and NAB2.

Country Status (22)

Country Link
EP (1) EP1097200A1 (id)
JP (1) JP2002520020A (id)
KR (1) KR20010071832A (id)
CN (1) CN1317045A (id)
AP (1) AP2001002038A0 (id)
AU (1) AU763713B2 (id)
BR (1) BR9912018A (id)
CA (1) CA2336805A1 (id)
EA (1) EA200100028A1 (id)
EE (1) EE200100020A (id)
HR (1) HRP20010025A2 (id)
HU (1) HUP0102835A3 (id)
ID (1) ID27742A (id)
IL (1) IL140533A0 (id)
IS (1) IS5788A (id)
NO (1) NO20010166L (id)
NZ (1) NZ509174A (id)
PL (1) PL345507A1 (id)
SK (1) SK382001A3 (id)
TR (1) TR200100622T2 (id)
WO (1) WO2000003014A1 (id)
YU (1) YU1901A (id)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928430D0 (en) * 1999-12-01 2000-01-26 Glaxo Group Ltd Screening
AU2001291019A1 (en) 2000-09-15 2002-03-26 Genvec, Inc. Method of modulating neovascularization
WO2004083435A1 (en) * 2003-03-17 2004-09-30 Julius-Maximilians-Uni Versität Würzburg Nab proteins and their use in diagnostic and therapeutic applications in heart disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection

Also Published As

Publication number Publication date
HRP20010025A2 (en) 2001-12-31
NO20010166L (no) 2001-03-06
NO20010166D0 (no) 2001-01-10
IL140533A0 (en) 2002-02-10
SK382001A3 (en) 2001-09-11
IS5788A (is) 2000-12-22
EP1097200A1 (en) 2001-05-09
YU1901A (sh) 2005-06-10
CA2336805A1 (en) 2000-01-20
AU763713B2 (en) 2003-07-31
KR20010071832A (ko) 2001-07-31
HUP0102835A2 (hu) 2001-11-28
EE200100020A (et) 2002-06-17
TR200100622T2 (tr) 2001-10-22
CN1317045A (zh) 2001-10-10
HUP0102835A3 (en) 2003-09-29
PL345507A1 (en) 2001-12-17
BR9912018A (pt) 2006-01-31
NZ509174A (en) 2003-08-29
ID27742A (id) 2001-04-26
EA200100028A1 (ru) 2001-08-27
JP2002520020A (ja) 2002-07-09
WO2000003014A1 (en) 2000-01-20
AU4791499A (en) 2000-02-01

Similar Documents

Publication Publication Date Title
NZ271756A (en) Human macrophage inflammatory proteins and coding sequences, their production and use
DK0910647T3 (da) Human DNase i hyperaktive varianter
ATE451929T1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
MXPA02002384A (es) Polipeptidos similares al factor de crecimiento de fibroblastos.
EP2679235A3 (en) Peptides and related molecules that modulate nerve growth factor activity
NZ500657A (en) Interleukin-3 gene therapy for cancer
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
NZ508505A (en) Treatment of wounds using an Egr-1 transcription factor polypeptide
NZ515964A (en) A method for the prophylaxis and/or treatment of medical disorders
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
Nakagami et al. Modification of a novel angiogenic peptide, AG30, for the development of novel therapeutic agents
AU3386100A (en) Anti-tnfalpha antibodies in therapy of asthma
ATE281159T1 (de) Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz
EP1114862A3 (de) Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
AP2001002038A0 (en) Pharmaceutical uses of NAB1 and NAB2.
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2000042166A3 (en) Methods and compositions for monitoring cellular processing of epitope-tagged beta-amyloid precursor protein
WO2002090552A3 (en) Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
DE69529235D1 (de) Menschliche dnase i varianten
WO1998054209A3 (en) Human mast cell function-associated antigen (mafa) and uses thereof
WO2002083060A3 (en) Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs
ATE403434T1 (de) Peptide zur modulierung der knorpelhomöostase
WO2000026362A3 (de) Proteine der stomatinfamilie und ihre verwendung als zielproteine für die schmerztherapie